News - Endo Pharmaceuticals, Neurological

Filter

Popular Filters

Through 2022, growth in the neuropathic pain drug market will be constrained by generics

05-11-2013

The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

US FDA to allow generic copies of Endo's Opana

13-05-2013

Endo Health Solutions (Nasdaq: ENDP) announced Friday (May 10) that the US Food and Drug Administration…

Endo Health SolutionsEndo PharmaceuticalsGenericsNeurologicalNorth AmericaOpana ERPharmaceuticalRegulation

Watson acquires Uteron Pharma; confirms Opana patent challenge

24-01-2013

US generic and specialty drugmaker Watson Pharmaceuticals (NYSE: WPI) says that it has completed the…

Endo PharmaceuticalsGenericsGrunenthalMergers & AcquisitionsNeurologicalNorth AmericaOpanaPatentsPharmaceuticalUteron PharmaWatson PharmaceuticalsWomen's Health

Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion

21-12-2012

The US District Judge Reggie Walton, of the District Court for the District of Columbia, has dismissed…

ActavisComtanEndo PharmaceuticalsGenericsImpax LaboratoriesLegalMylan LaboratoriesNeurologicalNorth AmericaOpana ERPharmaceutical

US patent settlements of Xopenex and Lidoderm

30-05-2012

US generics drug major Mylan (Nasdaq: MYL) has entered into a settlement agreement with Sunovion Pharmaceuticals,…

Dainippon Sumitomo PharmaEndo PharmaceuticalsGenericsLidodermMylan LaboratoriesNeurologicalNorth AmericaPatentsRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenex

Endo Pharma in $180 million deal with BioDelivery Sciences

08-01-2012

US drugmaker Endo Pharmaceuticals (Nasdaq: ENDP) has signed a worldwide license and development agreement…

BioDelivery SciencesBuprenorphineEndo PharmaceuticalsLicensingNeurologicalPharmaceutical

Endo Pharma pulls out of axomadol deal with Grunenthal

19-08-2011

USA-based Endo Pharmaceuticals (Nasdaq: ENDP) says that it is terminating its research program and collaboration…

axomadolEndo PharmaceuticalsGrunenthalLicensingNeurologicalPharmaceuticalResearch

Endo Pharma sues Mylan over Frova patent infringement

17-08-2011

US generic drugmaker Mylan (Nasdaq: MYL) yesterday confirmed that the company and its subsidiary Mylan…

Endo PharmaceuticalsFrovaFrovatriptan SuccinateGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaRegulation

Back to top